Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Latest findings on cancer to be presented at 10th AACR international conference

What: The 10th AACR International Conference on Frontiers in Cancer Prevention Research will bring together scientists to share the latest findings in genetics, chemoprevention and lifestyle choices that may prevent cancer.

4 Oct 2011

Kimmel Cancer Center at Jefferson celebrates two decades of caring and collaboration to beat cancer

From October forward, the Kimmel Cancer Center at Jefferson (KCC), a National Cancer Institute-designated cancer center, is celebrating 20 years of service to the community and the groundbreaking cancer research from the scientists and physicians who've provided an invaluable contribution to medical science and healthcare.

30 Sep 2011

Photocure, Ipsen partner to commercialise Hexvix for diagnosis of bladder cancer

Ipsen announces today a partnership with Photocure, a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology.

27 Sep 2011

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Aeterna Zentaris Inc., today announced positive interim data for the Phase 1 portion of its ongoing Phase 1/2 study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108.

26 Sep 2011

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.

26 Sep 2011

One in five cancer patients more likely to develop venous thromboembolism

An analysis of more than 30,000 cancer patients has shown that blood clots are a more common complication than doctors may realize, causing additional hospitalizations and driving up the cost of care, according to a study led by a Duke Cancer Institute researcher.

21 Sep 2011

Roxon plans to propagate tough stands on tobacco packaging

Health Minister Nicola Roxon plans to encourage other countries to follow Australia's push for plain-packaged tobacco at a major United Nations summit on chronic diseases today.

19 Sep 2011

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Aeterna Zentaris Inc. earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer.

14 Sep 2011

Tengion reinitiates enrollment in Neo-Urinary Conduit clinical trial for bladder cancer

Tengion, Inc. today announced that it has reinitiated enrollment of patients in the ongoing initial clinical trial of its lead product candidate, the Neo-Urinary Conduit, which is being evaluated in bladder cancer patients requiring a urinary diversion following bladder removal.

14 Sep 2011

Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD

Aeterna Zentaris Inc. today announced favorable top-line results of its completed Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency.

31 Aug 2011

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

Aeterna Zentaris Inc. today announced that a poster on its novel orally active anticancer Erk inhibitor, which includes AEZS-131, was presented at the 242nd American Chemical Society National Meeting held at the Colorado Convention Center in Denver, Colorado.

30 Aug 2011

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.

29 Aug 2011

MDxHealth first half 2011 commercial revenues increase 19%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today its 2011 half-year results.

25 Aug 2011

DMS receives NIH grant to establish Center of Biomedical Research Excellence

Under an $11-million grant from the National Institutes of Health (NIH), Dartmouth Medical School (DMS) will lead a network of northern New England institutions in recruiting, training, and supporting young quantitative biologists to teach and conduct research into the ways that genes and the environment work together to trigger and prevent disease.

23 Aug 2011

Research team reports first genetic sequencing of urothelial carcinoma

In an article published online this week in Nature Genetics, a University of Colorado Cancer Center team in partnership with universities in China and Denmark reports the first genetic sequencing of urothelial (transitional) carcinoma, the most prevalent type of bladder cancer.

12 Aug 2011

China Medical receives SFDA approvals for TOP2A and prostate cancer FISH detection kits

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it has received approvals for its prostate cancer FISH detection kit and Topoisomerase 2-alpha FISH detection kit from the State Food and Drug Administration of the People's Republic of China.

10 Aug 2011

Bladder cancer patients can benefit from radical cystectomy surgery

Bladder cancer patients who have radical surgery at university hospitals can benefit from excellent local control of the disease, acceptable clinical outcomes and low death rates, according to research in the August issue of the urology journal BJUI.

8 Aug 2011

OncoGenex second quarter revenue increases to $1.9 million

OncoGenex Pharmaceuticals, Inc. today provided an update on current events and activities and announced its second quarter financial results.

5 Aug 2011

Celldex second quarter net loss increases to $10.2 million

Celldex Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2011. Celldex reported a net loss of $10.2 million, or $0.27 per share, for the second quarter of 2011 compared to a net loss of $9.5 million, or $0.30 per share, for the second quarter of 2010.

3 Aug 2011

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Aeterna Zentaris Inc. today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.

27 Jul 2011

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Latest findings on cancer to be presented at 10th AACR international conference

Kimmel Cancer Center at Jefferson celebrates two decades of caring and collaboration to beat cancer

Photocure, Ipsen partner to commercialise Hexvix for diagnosis of bladder cancer

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

One in five cancer patients more likely to develop venous thromboembolism

Roxon plans to propagate tough stands on tobacco packaging

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Tengion reinitiates enrollment in Neo-Urinary Conduit clinical trial for bladder cancer

Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

MDxHealth first half 2011 commercial revenues increase 19%

DMS receives NIH grant to establish Center of Biomedical Research Excellence

Research team reports first genetic sequencing of urothelial carcinoma

China Medical receives SFDA approvals for TOP2A and prostate cancer FISH detection kits

Bladder cancer patients can benefit from radical cystectomy surgery

OncoGenex second quarter revenue increases to $1.9 million

Celldex second quarter net loss increases to $10.2 million

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in